Moolec Science SA Business Summary

Moolec Science SA (MLEC) is a pioneer in the molecular farming industry, utilizing genetically engineered crops to produce animal proteins and nutritional oils for the global food and dietary supplement markets. The company generates revenue through a B2B model focused on the sale of value-added food ingredients, structured across two primary segments: Ingredient Innovation, which includes flagship products like Piggy Sooy™ (porcine-protein soybeans), GLASO™ (high-GLA safflower oil), and Mycofood™ (fungal protein); and Biological Ag Expansion, which provides upstream regenerative agriculture inputs such as climate-resilient seeds and microbial solutions. Following a transformational 2025 business combination with Bioceres Group, Nutrecon, and Gentle Tech, Moolec has integrated precision fermentation and synthetic biology into its platform, reporting trailing twelve-month revenues of approximately $7.83 million as of late 2024. The company competes directly with molecular farming and alternative protein firms such as Alpine Bio, Mozza, Miruku, and PoLoPo, positioning itself as a vertically integrated leader that leverages existing agricultural infrastructure to achieve cost parity with traditional animal-based proteins. Moolec is led by a management team with deep expertise in biotechnology and the global food industry. Alejandro Antalich serves as Chief Executive Officer, bringing over 20 years of leadership experience from Nutrecon and the life sciences sector, while Valeria Falottico, formerly of dLocal and PwC, serves as Chief Financial Officer. The founding team includes Gaston Paladini (Director and former CEO), a fourth-generation meat industry veteran; Martin Salinas (Chief Technology Officer); and Henk Hoogenkamp (Chief Product Officer), a specialist in alternative protein applications. The company’s scientific direction is overseen by Chief Science Officer Dr. Amit Dhingra. Moolec is backed by notable strategic investors including Bioceres Group and Union Group, and its board is chaired by Gloria Montaron Estrada. As of early 2026, the leadership remains focused on maintaining Nasdaq compliance following a 15-for-1 share consolidation and a successful equity restoration plan that leveraged over $100 million in derecognition gains from subsidiary restructuring.